Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrahim, E. C.
Right arrow Articles by Paul, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrahim, E. C.
Right arrow Articles by Paul, P.
[Cancer Research 61, 6838-6845, September 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Tumor-specific Up-Regulation of the Nonclassical Class I HLA-G Antigen Expression in Renal Carcinoma1

El Chérif Ibrahim, Nadia Guerra, Marie-José Terrier Lacombe, Eric Angevin, Salem Chouaib, Edgardo D. Carosella, Anne Caignard and Pascale Paul2

CEA, Service de Recherches en Hémato-Immunologie, DSV/DRM, Hôpital Saint-Louis, Centre Hayem, 75010 Paris [E. C. I., E. D. C., P. P.]; Unité INSERM U487, Institut Gustave Roussy, PR1, 94805 Villejuif [N. G., S. C., A. C.]; Département d’Anatomopathologie, Institut Gustave Roussy, 94805 Villejuif [M-J. T. L.]; and Unité d’Immunologie, Laboratoire de Suivi Biologique des Nouvelles Thérapies, Institut Gustave Roussy, 94805 Villejuif, [E. A.], France


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
HLA-G is a nonclassical class I antigen mainly expressed at the maternofetal interface during pregnancy where it is thought to downmodulate maternal immune response against the semiallogeneic fetus. Recent studies indicate that ectopic up-regulation of HLA-G expression on melanoma cells may also favor their escape from antitumor immune response. HLA-G expression was here investigated on paraffin-embedded tumor and adjacent normal renal tissues of 18 renal cell carcinoma (RCC) patients. We provide evidence that HLA-G antigen is differentially expressed in carcinoma and normal renal cells and that up-regulation of this antigen in the tumor cells is more frequent than alterations of other MHC class I or class II antigens. We also demonstrated that HLA-G cell surface expression and secretion is maintained in a tumor cell line (DM) established from an HLA-G-positive RCC lesion. Furthermore, we show that type I ({alpha} and ß) and, in particular, type II ({gamma}) IFN treatment enhances steady-state mRNA levels and cell surface expression of HLA-G in the DM cell line. As several studies suggest that HLA-G displays various functional features that allow down-modulation of immune response in vitro, we propose that selective in vivo expression of HLA-G may participate in the impairment of antitumor immunity in RCC.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
RCC,3 the most common type of malignant tumor in the kidney, is a refractory tumor that does not respond to conventional therapies. Nevertheless, combined IL-2 and IFN-{alpha}2a treatment induce clinical responses suggesting that the immune system is triggered and may control the growth of these tumors (1) .

Like melanomas, RCC is considered as an immunogenic tumor, but RCC-associated antigens are rarely expressed limiting the vaccination trials in the patients. Although RCC contains high numbers of TILs, in vitro alterations of effector functions of these TILs have been described (2, 3, 4) . Production of various immunosuppressive molecules, like IL-10, transforming growth factor-ß, and gangliosides by the tumor cells (5, 6, 7, 8, 9) , were found to play a role in the different mechanisms leading to impairment of proliferative and cytolytic activity of TILs in vivo.

It is established that the level of HLA class I and class II expression is crucial to control recognition and activation of effector functions T cells toward tumor cells. In this context, the frequent alterations of HLA class I and class II expression in tumors of various origin is one of the mechanisms that allows tumor cells to escape immune surveillance (10) .

Up-regulation of expression of the nonclassical MHC class I antigen HLA-G was recently reported to modulate immune responses in pathological situations, such as cytomegalovirus infection (11) , transplantation, and tumors (reviewed in Ref. 12 ). HLA-G is characterized by low polymorphism and by the existence of at least seven alternatively spliced mRNA transcripts that encode both membrane-bound and soluble HLA-G protein isoforms (13, 14, 15) . In contrast to other MHC classical class I antigens (class Ia), HLA-G protein expression is restricted to maternofetal interface and thymus (reviewed in Ref. 16 ). Therefore, the involvement of HLA-G in down-modulation of the maternal immune response against the fetus was proposed (17) . Recent reports demonstrated the direct interaction of HLA-G killer cell antigen with at least three (KIRD) immunoglobulin-like inhibitory receptors: ILT2/LIR-1/CD85 (18, 19, 20) , ILT4 (20 , 21) , and KIR2DL4 (22, 23, 24) . Binding of HLA-G is assumed to inhibit the cytotoxic activity of NK cells and T lymphocytes bearing these receptors. In addition, the HLA-G5 soluble protein has been shown to trigger apoptosis in activated CD8+ T lymphocytes (25) . HLA-G also favors cell surface expression of another nonclassical class I antigen, HLA-E. Interaction of HLA-E with CD94/NKG2 heterodimers expressed on NK cells and subsets of CTLs results in delivery of inhibitory (NKG2-A) or triggering signals (NKG2-C), depending on the NKG2 subtype (reviewed in Ref. 26 ). Other roles for HLA-G in modulating cytokine production (27) , angiogenesis (28) , and NK cell migration (29) have been reported, indicating that up-regulation of this antigen in tumors may have various implications in the control of a tumor by the immune system.

The aim of this study was thus to investigate HLA-G expression in RCCs and adjacent normal renal tissues. Because contradictory data were reported concerning alterations of MHC antigen expression in RCC (30, 31, 32, 33, 34, 35, 36, 37, 38) , this analysis was extended to HLA class Ia and class II antigens expression. Moreover, we here report the first evidence of an RCC-derived tumor cell line, which maintains constitutive HLA-G cell surface protein expression and secretion in culture and additionally demonstrates that IFN treatment up-regulates its HLA-G expression.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tissue Specimens.
Tumor and adjacent normal renal samples were obtained from 18 patients with RCC who had undergone radical nephrectomy. None of the patients had received preoperative therapy. Tumors were staged according to TNM classification and examined for nuclear grade (I–IV according to Fuhrman classification). All specimens were fixed in acetic acid, formalin, and alcohol and embedded in paraffin. The tissues were cut at 4-µm thickness, mounted on pre-cleaned glass microscope slides (Menzel-Gläser, Braunscheig, Germany), deparaffinized using toluene, rehydrated through a graded series of ethanol, and rinsed in distilled water. Renal cell tumors were classified as conventional (clear cell) RCC, or papillary RCC, on the basis of findings in hematoxylin-, eosin-, and safranin-stained sections.

Cell Lines and Amniotic Fluids.
Renal tumor cell lines, as well as a normal renal cell primary culture, were derived from RCC and cultured as described previously (4) . The DM RCC cell line was derived from kidney resection of patient 13 (Table 1)Citation , whereas the VM RCC cell line was obtained from an RCC patient whose lesion could not be analyzed by immunohistochemistry in this series. An EBV-transformed B-cell line established from peripheral blood lymphocytes of patient DM, LCL (DM), was cultured in RPMI 1640 (Life Technologies, Inc.) supplemented with 10% FCS. The Tera-2 teratocarcinoma cells transfected either with pcDNA3.1/Hygro(-) expression vector alone (Invitrogen, Groningen, Netherlands) or with expression vector constructs containing cDNA of HLA-G5 and -G6 (G5pcDNA and G6pcDNA) were generated and cultured as described previously (15) . The human HLA-G-positive JEG-3 choriocarcinoma cell line (American Type Culture Collection, Rockville, MD) was cultured as specified. Amniotic fluids, used as positive controls for soluble HLA-G protein characterization, were obtained after voluntary interruption of normal pregnancies. Human recombinant IFN-{alpha}, ß, and {gamma} (IFN-{alpha}, -ß, and -{gamma}) were purchased from PeproTech (London, England) and added to cell culture medium for 48 h at defined concentrations.


View this table:
[in this window]
[in a new window]
  		Table 1 Characteristics of patients and biopsies immunostained for HLA class I and class II antigen

 
Immunocytochemistry.
Cells were cytocentrifuged on glass slides and fixed for 10 min in acetone at 4°C. Before immunohistochemistry analysis, deparaffinized tissue sections were submitted to epitope retrieval by high temperature in 10 mM sodium citrate buffer (pH 6.0) using a commercial microwave oven to optimize immunoreactivity. Slides were then rehydrated for 5 min in PBS containing 0.05% saponin and 10 mM HEPES buffer. Endogenous peroxidase activity was quenched by treating sections for 5 min at rt with 3% hydrogen peroxide in water. Nonspecific binding was prevented by applying 30% human serum for 20 min before staining with the primary mAb or with an IgG2a from a mouse plasmacytoma as a negative control (Sigma Chemical Co.) for 30 min at rt, using the EnVision+System, peroxidase (AEC; Dako, Glostrup, Denmark), according to the manufacturer’s instructions. All tissues were counterstained with Mayer’s hematoxylin solution for 7 min and coverslipped with permanent mounting media. A tissue was considered labeled positively if either normal or tumor renal cells or infiltrating cells contained visually detectable red chromogen in a membrane and/or cytoplasmic pattern.

Statistical Analysis.
The {chi}2 test was used for statistical analysis; Ps < 0.05 were considered significant.

Monoclonal Antibodies.
The primary antibodies used in this study were the anti-Leukocyte Common Antigen/CD45RB (clone PD7/26, mouse IgG1, 1/100 dilution; Dako), the anti-HLA-DP, -DQ, and -DR antigens (clone CR3/43, mouse IgG1, 1/50 dilution; Dako), the anti-HLA-DR antigen (clone B8.12.2, mouse IgG2b; Beckman Coulter-Immunotech, Marseille, France), the anti-CD31 antigen (clone JC/70A, mouse IgG1, 1/30 dilution; Dako), 87G: a purified mouse IgG2a recognizing both membrane-bound HLA-G1 and soluble HLA-G5 isoforms (2 and 5 µg/ml for flow cytometry and immunocytochemistry) kindly provided by D. Geraghty (Fred Hutchinson Cancer Research Center, Seattle, WA; Ref. 39 ), 4H84: a mouse IgG1 (1/600 dilution of ascitic fluid) anti-native and -denatured HLA-G heavy chain (40) kindly provided by S. Fisher and M. McMaster (University of California, San Francisco, CA), MEM-G/9 (Exbio, Praha, Czech Republik): a mouse IgG1 recognizing both membrane-bound HLA-G1 and soluble HLA-G5 isoforms (41) , HC-10: a mouse IgG2a against a determinant expressed preferentially on ß2m-free HLA-B and -C heavy chains (42) kindly provided by H. L. Ploegh (Harvard Medical School, Boston, MA), TP25.99: a mouse IgG1 (1/2 dilution of culture supernatant) recognizing a conformational and a linear determinant on associated and on ß2-m-free HLA-A, -B, -C, and -E but not HLA-G heavy chains, respectively, (43) generously provided by S. Ferrone (Roswell Park Cancer Institute, Buffalo, NY), B1.23.2: a mouse IgG2b recognizing an epitope expressed on both ß2-m-associated and -free HLA-B and -C heavy chains (44) , and 4E: a mouse IgG2a recognizing an epitope shared by HLA-B and -C heavy chains (45) .

RT-PCR Analysis.
Total mRNAs were extracted using the RNA NOW reagent (Biogentex, Seabrook, TX), according to the manufacturer’s recommendations, and analyzed as described previously (46) . Briefly, PCR amplifications were performed using exon 2-specific primer G.257F and exon5–exon6-specific primer G.1004R or exon 3-specific primer G.526 and intron 4-specific primer G.i4b, respectively, allowing the detection of all alternatively spliced HLA-G mRNAs and, specifically, HLA-G5 mRNA. Coamplification of ß-actin cDNA was carried out in each experiment with ß-actin amplimer sets (Clontech) for 16 cycles to normalize amounts of cDNAs in samples. Absence of contaminant DNA was controlled by concomitant amplification of the PCR mixture without template (H2O). PCR products were analyzed by electrophoresis in 1.5% agarose gel, and the specificity of PCR products was confirmed by Southern blot analysis using 32P-labeled oligonucleotide probe exon 2-specific G.R or intron-4-specific G.I4F. The same membranes were stripped in boiled 0.5% SDS solution and hybridized with a ß-actin probe.

Flow Cytometry.
Analysis was conducted using a FACs Vantage (Becton Dickinson) and an Epics XL (Beckman Coulter). Adherent cells were removed by trypsinization and washed in PBS containing 2% FCS. Appropriate concentrations of mAbs were added to 2.105 cells in 50 µl of PBS containing 2% FCS and incubated for 30 min at 4°C. Cells were stained with an isotype-matched irrelevant antibody to evaluate nonspecific binding. Cells were washed with PBS and incubated with phycoerythrin-conjugated goat antimouse immunoglobulin (Beckman Coulter-Immunotech) at 1/50 dilution for 30 min at 4°C. After washing and fixing in PBS containing 0.5% formaldehyde, a minimum of 5000 cells were analyzed by flow cytometry.

Western Blot Analysis.
Cells were washed with PBS and lysed in lysis buffer [50-mm Tris-HCl (pH 7.4), 150-mm NaCl, 1% NP40] containing protease inhibitors (Complete; Roche Diagnostics, Mannheim, Germany). After centrifugation at 15,000 x g at 4°C for 20 min, supernatants (20 µl) were supplemented with 6 x Laemmli buffer. All samples were heated for 5 min at 95°C before loading on a 12% SDS-PAGE. Proteins were then electroblotted onto polyvinylidene difluoride membrane (Hybond-P; Amersham). The filters were blocked with 5% nonfat dried milk in PBST for 1 h at rt and incubated with 4H84, in PBST containing 2.5% nonfat dried milk overnight at 4°C. After washing with PBST, the membranes were incubated with horseradish peroxidase-conjugated goat antimouse immunoglobulin antibody (Amersham) for 45 min at rt. After additional washes in PBST, signals were detected using Enhanced Chemiluminescence Plus reagent (Amersham).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Immunohistochemical Analysis of HLA-G Protein Expression in RCC and Normal Kidney.
HLA-G expression was analyzed by immunohistochemistry in paraffin-embedded sections obtained from 18 randomly selected RCC patients using the HLA-G-specific 4H84 mAb (Table 1)Citation . A high incidence of HLA-G expression was observed in RCC as 11 of 18 tumors exhibited mainly a membranous/Golgi immunoreactivity with the 4H84 mAb. HLA-G expression was mostly evidenced in tumor cells (10 of the 11 positive cases, Fig. 1ACitation ) and rarely detected in inflammatory infiltrating cells (Fig. 1B)Citation ; normal renal tissue removed on the same kidney at a distance from the tumor rarely expressed HLA-G (1 case, within scattered inflammatory infiltrating cells). No correlation between HLA-G expression and clinical parameters (patient’s age and sex, TNM stage) could be established from this study.



View larger version (122K):
[in this window]
[in a new window]
  		Fig. 1. Immunochemical analysis of HLA-G antigens expression in serial sections of RCC lesions. In A, tumor cells within the RCC lesion of patient 13 (Table 1)Citation were stained positively using the anti-HLA-G antigen 4H84 mAb (b), the anti-HLA-B and -C molecule HC-10 mAb (c), and the anti-HLA class II antigen CR3/43 mAb (d). In contrast, the immune infiltrating cells revealed with an anti-CD45RB mAb (e) and the CD31-positive capillary endothelial cells (f) were negative for HLA-G expression. In the same kidney, HLA-G antigens were not detected in normal cells (g). HLA-G expression was detected in the cytocentrifuged DM tumor cells derived from patient 13 (Table 1)Citation using the HLA-G-specific antibody 87G (i). Isotype-matched mAbs were used as controls for nonspecific binding on RCC (a) and normal kidney (h) sections, as well as on cytocentrifuged DM RCC cells (j). In B, a papillary tumor corresponding to a kidney resected from patient 9 (Table 1)Citation contains HLA-G-positive cells (b), identified as inflammatory infiltrating cells by their staining by anti-CD45-RB (c) and anti-HLA class II mAbs (d). All cells, including tumor cells, were stained by the anticlassical class I HC-10 mAb (e). The normal tissue resected from the same kidney was devoid of HLA-G staining (g) despite a strong staining with Leukocyte Common Antigen mAb in the numerous infiltrating cells (h). The specificity of the HLA-G stainings on these tissue sections was confirmed by the use of an irrelevant isotype-matched mAb (a and f). Original magnification: A, x80; B, a–e, x120, f–h, x80.

 
Comparative Analysis of HLA-G versus HLA Class Ia and Class II Expression in RCC and Normal Kidney.
Concomitantly to HLA-G expression analysis, serial tissue sections were stained for HLA class Ia and class II expression (Table 1)Citation . Except for three cases, all normal components of the human nephron, such as the glomerular elements (parietal cells of Bowman’s capsule, podocytes, and mesangial cells) and all of the epithelial cells lining the proximal tubules and the distal collecting ducts, reacted positively with the anti-HLA-B and -C and HC-10 mAb. Heterogeneous MHC class I reactivity was observed, staining being more intense on the glomeruli and interstitial cells than in tubular structures. Moreover, a stronger class I HC-10 mAb staining was observed in malignant tissue in comparison with normal kidney tissue sections. The carcinoma cells exhibited a dense cell membrane staining pattern. Although use of the monomorphic HC-10 class I mAb does not allow characterization of allele- or locus-specific class I defects, total loss of class Ia antigen expression was never observed in RCC specimens. HLA class I loss foci were evidenced within a subset of epithelial cells in one RCC but were also observed in normal tissue of 3 patients (Table 1)Citation .

The HLA class II immunoreactivity evidenced with the CR3/43 mAb was more heterogeneous and was observed in both healthy and tumor tissues. Inflammatory components as well as mesangial and endothelial cells of glomeruli and intertubular capillaries were positive for expression of MHC class II antigens, whereas podocytes were negative for immunoreactivity with the CR3/43 mAb. Moreover, HLA class II antigens were detected at a significantly lower frequency in normal tubular cells (50%) than in carcinoma cells (83.3%, P < 0.05). No significant correlation could be established between the presence or lack of HLA-G expression in tumor cells and HLA class II detection in normal and tumor tubular cells.

Characterization of Transcripts and Proteins Corresponding to Membrane-bound and Soluble HLA-G Isoforms in a Renal Carcinoma-derived Cell Line.
Permanent tumor cell lines were successfully established from some RCC, and normal renal cells were obtained from normal renal tissue (4) . Levels of HLA-G mRNA transcripts were analyzed in these cell lines by RT-PCR using pan-HLA-G primers (G.257F/G.1004R) that detect most of the HLA-G alternative transcripts. Size discrimination of RT-PCR products corresponding to alternatively spliced transcripts that exclude one or two exons of the gene allows identification of HLA-G1, -G5, -G2 and -G4 (migrating at the same size), and -G3 transcripts. A high level of HLA-G transcripts (Fig. 2ACitation , top panel), comparable with that observed in the JEG-3 choriocarcinoma-positive control cell line, was observed in DM tumor cell line derived from RCC 13 (Table 1)Citation , which exhibited intense HLA-G protein staining of tumor cells (Fig. 1A, e)Citation . In contrast to the high level of HLA-G transcripts detected in dissociated tumor cells (T0) and in the established DM renal carcinoma cell line, the autologous B-EBV cell line derived from patient 13 [LCL (DM)] exhibited a basal level of HLA-G transcripts. HLA-G alternative transcripts were also detected both in a normal kidney primary cell culture (PAS) and in another renal carcinoma-derived cell line (VM), but HLA-G mRNA levels were lower than those revealed in DM tumor cells, using the semiquantitative normalization with the ß-actin transcripts.



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 2. HLA-G is expressed in the DM tumor cell line (derived from RCC patient 13) as a membrane-bound and soluble protein. A, RT-PCR detection of HLA-G mRNAs in dissociated RCC lesions (T0) and in the corresponding derived tumor cell lines (VM and DM). Top panel, detection of HLA-G alternative transcripts resulting from amplification with pan-HLA-G primers G.257F (exon 2) and G.1004R (exon 5/exon 6): HLA-G5, 886 bp; HLA-G1, 764 bp; HLA-G2, 488 bp; HLA-G4, 491 bp; and HLA-G3, 215 bp. Bottom panel, specific amplification of HLA-G5 transcripts corresponding to the soluble HLA-G5 protein (489 bp) with primers G.526 (exon 3) and G.i4b (intron 4). HLA-G-specific transcripts were revealed by hybridization with either the exon 2-specific G.R probe (top panel) or an intron 4-specific G. I4F probe (bottom panel). Normal renal cells and the B-EBV cell line autologous to DM tumor cells, LCL (DM), were included in the analysis. Absence of contaminant DNA was controlled by concomitant amplification of the PCR mixture without a template (H2O). ß-actin PCR products coamplified in the same reaction were detected on the same membrane. B, flow cytometry analysis using B1.23.2 (anti-HLA-B and -C alleles), TP25.99 (anti-HLA-A, -B, -C, and -E), and 87G (anti-HLA-G1 and -G5) mAbs depicted as filled histograms (MFI) and open histograms (mouse isotypic IgG2a control). C, whole-cell protein extracts analyzed by Western blot probing with the HLA-G-specific 4H84 mAb. Bands corresponding to HLA-G1, -G5, and the putative -G2 protein isoforms are indicated by arrows. D, Western blot analysis of HLA-G5 soluble isoform detected in DM supernatants. The Tera2-pcDNA and -G6 transfectants were used as negative controls, and Tera2-G5 transfected cell extracts were used as a positive control for detection of soluble HLA-G proteins. Amniotic fluid (Amniot. F.438) is a physiological positive control for soluble HLA-G protein detection.

 
Specific RT-PCR analysis of transcripts corresponding to soluble HLA-G5 reveals that soluble isoform-encoding HLA-G5 transcripts were present in DM cells both in tumor-dissociated cells and in the established tumor cell line, whereas only a very faint signal was detectable in the autologous B-EBV cells (Fig. 2ACitation , bottom panel). Altogether, these results suggest that up-regulation of HLA-G protein expression is likely to result from specific transcriptional activation of HLA-G gene expression in the tumor cells derived from patient 13.

We then investigated if up-regulation of HLA-G transcript levels in the DM renal carcinoma cell line could be associated to cell surface expression of HLA-G1 protein in tumor cells. In accordance with the high rate of HLA-G transcripts in DM tumor cells, HLA-G1 protein expression was detected on DM cells by flow cytometry analysis using the HLA-G-specific mAbs 87G (Fig. 2B)Citation and MEM-G/9 (data not shown). In contrast, cells exhibiting lower levels of HLA-G transcripts, LCL (DM), normal kidney cells (PAS), and VM renal carcinoma cells, were devoid of HLA-G cell surface expression. Six additional renal carcinoma cell lines derived from patients that either expressed HLA-G on tumor cells ex vivo (patients 2, 8, and 9) or not (patients 1, 17, and 18) were negative for HLA-G cell surface expression (data not shown).

Concomitant flow cytometry analysis of class Ia HLA antigens expression in the same cell lines using B1.23.2 (HLA-B and -C alleles) and TP25.99 (HLA-A, -B, -C, and -E but not -G) mAbs revealed that these cell lines expressed classical HLA class I antigens (Fig. 2B)Citation .

A high and homogeneous HLA-G protein expression in DM tumor cell line was also confirmed by immunocytochemistry (Fig. 1A, i)Citation . Western blot analysis of HLA-G proteins using the 4H84 mAb allowed detection of specific signals corresponding to HLA-G1 and -G5 proteins in whole cell extracts from DM cells and in positive control JEG-3 cells but not in the DM (LCL) cells (Fig. 2C)Citation . Interestingly, a 30-kDa migrating band that may correspond to the HLA-G2 isoform was also observed in DM carcinoma cells.

Secretion of the soluble HLA-G protein by DM tumor cells was assessed by Western blot analysis of cultured cell supernatants (Fig. 2D)Citation . A band of ~37 kDa, corresponding to the size of the HLA-G5 protein in HLA class I-negative Tera-2 cells transfected with an HLA-G5 expression vector, was revealed in DM tumor cells, whereas it was not detectable in DM (LCL) cells or in control Tera-2 cells transfected with empty expression vector. As expected, a high level of HLA-G5 protein was also detected in amniotic fluid used as a positive control.

IFN Treatment Enhances Both HLA Class Ia and HLA-G Cell Surface Protein Expression in the DM Renal Carcinoma Cell Line.
Flow cytometry analysis of cell surface HLA-G and HLA class Ia and class II expression was conducted after 48 h of treatment of DM cells with various doses of type I (IFN-{alpha}: 200, 400, 1000, and 2500 units/ml and IFN-ß: 250, 500, 1000, and 2000 units/ml) or type II IFNs (IFN-{gamma}: 40, 80, 200, and 500 units/ml). All three IFNs used induced a 2–4-fold increase of cell surface expression of both classical class I antigens (HLA-B and -C, using the B1.23.2 and 4E mAbs) and the full-length membrane-bound HLA-G1 isoform (specifically revealed by 87G and MEM-G/9 mAbs), even at the lowest concentrations of IFN used. Optimal enhancement of MHC class I antigen cell surface expression was obtained using 2500 (IFN-{alpha}), 1000 (IFN-ß), and 500 units/ml (IFN-{gamma}; Fig. 3Citation ). IFN-{gamma} was the sole IFN to induce HLA-DR antigen expression as detected by the B8.12.2 mAb (data not shown) and is also the most effective inducer of HLA-G expression in DM cells.



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 3. Enhancement of HLA-G expression by IFN treatment in the DM RCC cell line. DM tumor cells were incubated for 48 h in culture medium alone or supplemented with IFN-{alpha} (2500 units/ml), IFN-ß (1000 units/ml), or IFN-{gamma} (500 units/ml) and were analyzed by flow cytometry using various mAbs directed against HLA class I epitopes (87G and MEM-G/9: anti-HLA-G antigens; B1.23.2 and 4E: anti-HLA-B and C antigens; TP25.99: anti-HLA-A, -B, -C, and -E but not HLA-G). The relative induction of HLA-G cell surface expression derived from at least three independent experiments is expressed as a ratio between (MFI in cells treated by IFN) and (MFI in control cells); bars, SD.

 
A comparative RT-PCR analysis of type I and II IFN treatment revealed only a slight increase of the steady-state levels of HLA-G mRNA levels (which is more pronounced for the HLA-G5 soluble isoform encoding transcript) by IFN-{gamma} treatment (data not shown), suggesting that posttranscriptional mechanisms may be implicated in the IFN-mediated enhancement of HLA-G protein expression in DM cells. In contrast, IFN-{gamma} treatment of HLA-G-negative renal tumor cell lines (VM and cells derived from patients 1, 2, 8, 9, and 17) did not induce HLA-G cell surface expression (data not shown).


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The major characteristic of the MHC class I HLA-G gene resides in its tissue-restricted pattern of protein expression in vivo in healthy individuals. However, recent studies indicate that the expression of this placental antigen can be activated in malignancies, including melanoma and colorectal cancer (47, 48, 49) . Considering the immunomodulatory function assigned to date to HLA-G molecules, its expression in malignant cells may represent one of the various mechanisms used by tumor cells to thwart the immune response (50) . Our aim was thus to evaluate HLA-G protein expression in RCC in comparison with normal matched renal tissue. HLA-G expression was detected only once within subsets of normal epithelial tubular cells. In contrast, expression of HLA-G antigens was observed in tumor cells of a significant number of RCC lesions (10 of 18), suggesting that tumor-specific activation of HLA-G expression frequently occurs in RCC malignant cells. Recruitment of patients matching that of RCC in population (age, sex, and clear cell:papillary RCC ratio) did not allow any correlation of HLA-G expression with histopathological or clinical parameters of the disease. In this series of 18 RCC specimens, 16 were of the conventional type (clear cell), whereas 2 were papillary.

Most RCC sections analyzed exhibited peripheral 4H84 immunostaining of tumor cells, compatible with a cell surface expression of HLA-G molecules. Confirming immunohistochemical analysis, the detection of membrane-bound HLA-G1 and secreted HLA-G5 protein isoforms in tumor cells derived from an HLA-G-positive tumor strongly supports the notion that HLA-G proteins are expressed in vivo by RCC tumor cells and released as soluble factors within the tumor. As observed previously in melanoma (47) , HLA-G protein expression in RCC tissue sections correlated to specific activation of HLA-G alternative transcript levels in the dissociated tumor or RCC-derived cell line. The present data showing that HLA-G expression can be maintained in vitro in an RCC-derived cell line contradicts previous reports that led to the conclusion that tumors do not express HLA-G proteins (51, 52, 53) . Our previous report on melanoma biopsies and cell lines and the present study on RCC still outline that the incidence of HLA-G expression is probably higher in vivo than that detected in established tumor cell lines.

Whereas a consensus was reached concerning expression of HLA class I antigens in normal kidneys (30 , 34 , 35 , 54) , reported data concerning HLA class Ia expression in RCC tissues remains contradictory. Considering the high incidence of HLA-G expression in RCC reported in this study, the use of the W6/32 mAb that detects all ß2-m-associated HLA class I antigens, including HLA-E and HLA-G, to analyze HLA class I expression in RCC may partly explain the conflicting results concerning HLA class Ia antigen expression in primary RCCs as compared with normal proximal tubules (30, 31, 32, 33, 34) . This study is the first to attempt a combined analysis of MHC gene expression, allowing discrimination between classical and nonclassical class I antigen expression, in the same RCC patients. In contrast to W6-32 or anti-ß2-m mAb, HC-10 mAb recognizes a determinant shared by HLA-B and -C heavy chains (42) and allows detection of HLA-B and -C class I loss variants in paraffin-embedded tissues but does not detect HLA-G or -E class Ib antigens. Although our analysis using HC-10 may have underestimated the detection of selective HLA-A class I or allele-specific HLA class I-negative loss variants observed previously in advanced RCC (32 , 55) , use of this antibody combined to HLA-G detection gives new insight for better comprehension of MHC class I alterations in tumors. Our analysis indicates that tumor-specific HLA-G class I up-regulation is a frequent event in RCC. This study also reveals that total loss of HLA-B and -C antigen expression is rarely observed in RCC and that focal loss of class I expression does not appear to be a hallmark of tumors as it is also detected in normal renal tissue.

Discrepancies were also reported in the literature concerning HLA class II detection in normal renal cells and RCC. Whereas studies described HLA-II-negative normal tubular cells (33 , 35) , others report heterogeneous staining in normal tissue (31 , 36 , 54 , 56) . Previous studies analyzing MHC class II antigen expression in RCC led to conflicting conclusions as a total lack of HLA class II antigens in renal carcinoma cells (33 , 36) , staining of 50% of RCC (31) or most if not all RCC (35 , 37) . Our analysis of HLA class II antigen expression, based on the reactivity of the CR3/43 mAb recognizing a shared determinant of HLA-DP, -DQ, and -DR molecules, indicates enhanced expression of MHC class II antigens in renal carcinoma as compared with normal tissues (31 , 37 , 38) . In contrast to HLA-G up-regulation, which is only detected in the tumor tissue, MHC class II antigen expression appears less specific of the tumor site as it is also observed in normal tissue of some patients.

The mechanisms underlying up-regulation of HLA-G gene expression are poorly understood and may involve transcriptional activation by the tumor microenvironment. Factors such as stress or IL-10 have been shown to promote HLA-G gene expression (46 , 57) and involve regulatory pathways that are not shared by other MHC class I genes. IFNs are potent inducers of HLA-G expression (58, 59, 60, 61) , and regulatory mechanisms that control transcriptional up-regulation of HLA-G antigens have been shown to be distinct from those implicated in up-regulation of classical MHC class I and II genes (62 , 63) . As expected (64) , IFNs up-regulate MHC class Ia antigen expression on the DM tumor cell line. We also show that IFN-{gamma} and, to a lesser extent, type I IFN ({alpha} and ß) induced HLA-G1 surface expression in this cell line. In accordance to previous experiments using RCC cell lines (31) , IFN-{gamma}, but not type I IFNs, also induces cell surface expression of HLA-DR molecules on DM tumor cells. Levels of HLA-G5 transcripts, encoding the soluble HLA-G protein isoform, were also up-regulated upon IFN-{gamma} treatment in this RCC cell line.

Altogether, our results indicate that HLA-G protein expression and secretion is up-regulated in a tumor-specific manner in RCCs and thus appears to be more characteristic of the malignant phenotype of renal cells than alterations of other HLA class Ia and class II antigens.

Previous description of HLA-G as a down-modulator of both NK and T lymphocyte effector cell functions in vitro allows speculation on the impact of HLA-G tumor-specific expression in modulating an efficient antitumor immune response (18, 19, 20, 21, 22, 23, 24 , 65) . Recent data have indeed shown that the interaction of HLA-C molecules expressed by the DM tumor cells with the p58.2 inhibitory receptor mediates inhibition of cytotoxic activity of in situ-amplified p58-positive T cells (4) . Additional inhibition of cytotoxic activity by tumor-specific p58-positive T cells coexpressing ILT-2 receptor through HLA-G engagement was also investigated (data not shown). Masking of HLA-G on DM target cells or ILT-2 receptors on effector T cells did not result in additional enhancement of cytotoxicity, suggesting that the p58.2 inhibitory receptors provide the dominant inhibitory signal in these T cells (4) . Lack or down-regulation of MHC class I alleles ligand of KIRs in some patients or presence of effector cell subsets that preferentially recognize HLA-G may still be of importance in vivo. Furthermore, according to previous studies, alternative roles for HLA-G, such as modulation of cytokine production (27) , induction of activated T lymphocyte apoptosis (25) , inhibition of NK cells migration (29) , or alteration of T-cell activation by HLA-G-positive professional antigen presenting cells, may also play a role in modulating the immune response against tumors in vivo and remain to be investigated.

In addition to being an additional immune escape mechanism, aberrant activation of HLA-G in melanoma has been proposed as a rationale for the unresponsiveness to IFN-{alpha} therapy in melanoma patients (48) . Our finding that IFNs also enhance HLA-G expression in some RCC tumor cells may suggest adverse effects of such treatment in favoring immune responses in some patients. Characterization of HLA-G could thus contribute to better prediction and monitoring of RCC patients that will better benefit from IFN-{alpha} therapy.


   ACKNOWLEDGMENTS
 
We thank M. McMaster, S. Fisher, D. Geraghty, S. Ferrone, and H. L. Ploegh for the kind gift of antibodies and L. Gourand for providing amniotic fluid. We also thank J-A. Gavigan for editing the manuscript. Finally, we thank E. Savariou, R. Nancel, and B. Boursin for photographical work.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by grants from the French Commissariat èa l’Energie Atomique, the Association pour la Recherche sur la Cancer, and the Ligue Nationale Contre le Cancer. E. C. I. is a recipient of a grant from the Ministere de l’Education Nationale de la Recherche et de la Technologie. Back

2 To whom requests for reprints should addressed, at CEA, Service de Recherches en Hémato-Immunologie, DSV/DRM, IUH Hôpital Saint-Louis, Centre Hayem, 1 avenue Claude Vellefaux, 75010 Paris, France. Phone: 33 (0) 1 53 72 21 42; Fax: 33 (0) 1 48 03 19 60; E-mail: paul{at}dsvidf.cea.fr Back

3 The abbreviations used are: RCC, renal cell carcinoma; mAb, monoclonal antibody; IL, interleukin; TIL, tumor-infiltrating lymphocyte; NK, natural killer; rt, room temperature; RT-PCR, reverse transcription-PCR; TNM, Tumor-Node-Metastasis; PBST, PBS containing 0.2% Tween 20; MFI, mean of fluorescence intensity. Back

Received 2/26/01. Accepted 7/13/01.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Negrier S., Escudier B., Lasset C., Douillard J. Y., Savary J., Chevreau C., Ravaud A., Mercatello A., Peny J., Mousseau M., Philip T., Tursz T. Recombinant human interleukin-2, recombinant human interferon {alpha}-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’Immunothérapie. N. Engl. J. Med., 338: 1272-1278, 1998.[Abstract/Free Full Text]
  2. Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O’Shea J. J., Klein E., Bukowski R. M., Ochoa A. C. Loss of T-cell receptor {zeta} and p56lck in T-cell infiltrating human renal cell carcinoma. Cancer Res., 53: 5613-5616, 1993.[Abstract/Free Full Text]
  3. Uzzo R. G., Rayman P., Kolenko V., Clark P. E., Bloom T., Ward A. M., Molto L., Tannenbaum C., Worford L. J., Bukowski R. M., Tubbs R., Hsi E. D., Bander N. H., Novick A. C., Finke J. H. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res., 5: 1219-1229, 1999.[Abstract/Free Full Text]
  4. Guerra N., Guillard M., Angevin E., Echchakir H., Escudier B., Moretta A., Chouaib S., Caignard A. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood, 95: 2883-2889, 2000.[Abstract/Free Full Text]
  5. Nakagomi H., Pisa P., Pisa E. K., Yamamoto Y., Halapi E., Backlin K., Juhlin C., Kiessling R. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer, 63: 366-371, 1995.[Medline]
  6. Wang Q., Redovan C., Tubbs R., Olencki T., Klein E., Kudoh S., Finke J., Bukowski R. M. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int. J. Cancer, 61: 780-785, 1995.[Medline]
  7. Knoefel B., Nuske K., Steiner T., Junker K., Kosmehl H., Rebstock K., Reinhold D., Junker U. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-ß 1 in primary cultures and modulate T lymphocyte blast transformation. J. Interferon Cytokine Res., 17: 95-102, 1997.[Medline]
  8. Uzzo R. G., Rayman P., Kolenko V., Clark P. E., Cathcart M. K., Bloom T., Novick A. C., Bukowski R. M., Hamilton T., Finke J. H. Renal cell carcinoma-derived gangliosides suppress nuclear factor-{kappa}B activation in T cells. J. Clin. Investig., 104: 769-776, 1999.[Medline]
  9. Ménétrier-Caux C., Bain C., Favrot M. C., Duc A., Blay J. Y. Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br. J. Cancer, 79: 119-130, 1999.[Medline]
  10. Marincola F. M., Jaffee E. M., Hicklin D. J., Ferrone S. Escape of human solid tumours from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 74: 181-263, 2000.[Medline]
  11. Onno M., Pangault C., Le Friec G., Guilloux V., André P., Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J. Immunol., 164: 6426-6434, 2000.[Abstract/Free Full Text]
  12. Carosella E. D., Paul P., Moreau P., Rouas-Freiss N. HLA-G, and -E. fundamental and patophysiological aspects. Immunol. Today, 21: 532-534, 2000.[Medline]
  13. Ishitani A., Geraghty D. E. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl. Acad. Sci. USA, 89: 3947-3951, 1992.[Abstract/Free Full Text]
  14. Kirszenbaum M., Moreau P., Gluckman E., Dausset J., Carosella E. D. An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc. Natl. Acad. Sci. USA, 91: 4209-4213, 1994.[Abstract/Free Full Text]
  15. Paul P., Adrian-Cabestre F., Ibrahim E., Lefebvre S., Khalil-Daher I., Quiles R. M., Bermond F., Dausset J., Carosella E. D. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum. Immunol., 61: 1138-1149, 2000.[Medline]
  16. Le Bouteiller P., Blaschitz A. The functionality of HLA-G is emerging. Immunol. Rev., 167: 233-244, 1999.[Medline]
  17. Kovats S., Main E. K., Librach C., Stubblebine M., Fisher S. J., DeMars R. A class I antigen. HLA-G, 248: 220-223, 1990.
  18. Colonna M., Navarro F., Bellon T., Llano M., Garcièa P., Samaridis J., Angman L., Cella M., Lopez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med., 186: 1809-1818, 1997.[Abstract/Free Full Text]
  19. Navarro F., Llano M., Bellon T., Colonna M., Geraghty D. E., Lopez-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur. J. Immunol., 29: 277-283, 1999.[Medline]
  20. Allan D. S., Colonna M., Lanier L. L., Churakova T. D., Abrams J. S., Ellis S. A., McMichael A. J., Braud V. M. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA-G) bind to peripheral blood myelomonocytic cells. J. Exp. Med., 189: 1149-1156, 1999.[Abstract/Free Full Text]
  21. Colonna M., Samaridis J., Cella M., Angman L., Allen R. L., O’Callaghan C. A., Dunbar R., Ogg G. S., Cerundolo V., Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol., 160: 3096-3100, 1998.[Abstract/Free Full Text]
  22. Cantoni C., Verdiani S., Falco M., Pessino A., Cilli M., Conte R., Pende D., Ponte M., Mikaelsson M. S., Moretta L., Biassoni R. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. Eur. J. Immunol., 28: 1980-1990, 1998.[Medline]
  23. Rajagopalan S., Long E. O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med., 189: 1093-1100, 1999.[Abstract/Free Full Text]
  24. Ponte M., Cantoni C., Biassoni R., Tradori-Cappai A., Bentivoglio G., Vitale C., Bertone S., Moretta A., Moretta L., Mingari M. C. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc. Natl. Acad. Sci. USA, 96: 5674-5679, 1999.[Abstract/Free Full Text]
  25. Fournel S., Aguerre-Girr M., Huc X., Lenfant F., Alam A., Toubert A., Bensussan A., Le Bouteiller P. Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J. Immunol., 164: 6100-6104, 2000.[Abstract/Free Full Text]
  26. Lopez-Botet M., Bellon T., Llano M., Navarro F., Garcia P., de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum. Immunol., 61: 7-17, 2000.[Medline]
  27. Maejima M., Fujii T., Kozuma S., Okai T., Shibata Y., Taketani Y. Presence of HLA-G-expressing cells modulates the ability of peripheral blood mononuclear cells to release cytokines. Am. J. Reprod. Immunol., 38: 79-82, 1997.
  28. Blaschitz A., Lenfant F., Mallet V., Hartmann M., Bensussan A., Geraghty D. E., Le Bouteiller P., Dohr G. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur. J. Immunol., 27: 3380-3388, 1997.[Medline]
  29. Dorling A., Monk N. J., Lechler R. I. HLA-G inhibits the transendothelial migration of human NK cells. Eur. J. Immunol., 30: 586-593, 2000.[Medline]
  30. Natali P. G., Bigotti A., Nicotra M. R., Viora M., Manfredi D., Ferrone S. Distribution of human class I (HLA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res., 44: 4679-4687, 1984.[Abstract/Free Full Text]
  31. Gastl G., Ebert T., Finstad C. L., Sheinfeld J., Gomahr A., Aulitzky W., Bander N. H. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon {gamma}. J. Urol., 155: 361-367, 1996.[Medline]
  32. Luboldt H-J., Kubens B. S., Rübben H., Grosse-Wilde H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res., 56: 826-830, 1996.[Abstract/Free Full Text]
  33. Droz D., Zachar D., Charbit L., Gogusev J., Chrétien Y., Iris L. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am. J. Pathol., 137: 895-905, 1990.[Abstract]
  34. Cordon-Cardo C., Fuks Z., Drobnjak M., Moreno C., Eisenbach L., Feldman M. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res., 51: 6372-6380, 1991.
  35. Tomita Y., Nishiyama T., Fujiwara M., Sato S. Immunohistochemical detection of major hisocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. Br. J. Cancer, 62: 354-359, 1990.[Medline]
  36. Heinemann D., Smith P. J. B., Symes M. O. Expression of histocompatibility antigens and characterisation of mononuclear cell infiltrates in human renal cell carcinoma. Br. J. Cancer, 56: 433-437, 1987.[Medline]
  37. Brasanac D., Markovic-Lipkocski J., Hadzi-Djokic J., Müller G. A., Müller C. A. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopatholoical data. Neoplasma, 46: 173-178, 1999.[Medline]
  38. Ohmori T., Okada K., Arita N., Watanabe Y., Miyazaki T., Tabei R. Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol. Histopathol., 10: 789-794, 1995.[Medline]
  39. Lee N., Malacko A. R., Ishitani A., Chen M-C., Bajorath J., Marquardt H., Geraghty D. E. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity, 3: 591-600, 1995.[Medline]
  40. McMaster M., Zhou Y., Shorter S., Kapasi K., Geraghty D., Lim K-H., Fisher S. HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J. Immunol., 160: 5922-5928, 1998.[Abstract/Free Full Text]
  41. Fournel S., Huc X., Aguerre-Girr M., Solier C., Legros M., Praud-Brethenou C., Moussa M., Chaouat G., Berrebi A., Bensussan A., Lenfant F., Le Bouteiller P. Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules. Tissue Antigens, 55: 510-518, 2000.[Medline]
  42. Stam N. J., Spits H., Ploegh H. L. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J. Immunol., 137: 2299-2306, 1986.[Abstract]
  43. Desai S. A., Wang X., Noronha E. J., Zhou Q., Rebmann V., Grosse-Wilde H., Moy F. J., Powers R., Ferrone S. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on ß2-microglobulin-associated and ß2-microglobulin-free HLA class I heavy chains. J. Immunol., 165: 3275-3283, 2000.[Abstract/Free Full Text]
  44. Rebaï N., Malissen B. Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens, 22: 107-117, 1983.[Medline]
  45. Yang S. Y., Morishima Y., Collins N. H., Alton T., Pollack M. S., Yunis E. D., Dupont B. Comparaison of one-dimensional IEF patterns for serologically detectable HLA-A and B allotypes. Immunogenetics, 19: 217-231, 1984.[Medline]
  46. Ibrahim E. C., Morange M., Dausset J., Carosella E. D., Paul P. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones, 5: 207-218, 2000.[Medline]
  47. Paul P., Adrian-Cabestre F., Le Gal F. A., Khalil-Daher I., Le Danff C., Schmid M., Mercier S., Avril M. F., Dausset J., Guillet J-G., Carosella E. D. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res., 59: 1954-1960, 1999.[Abstract/Free Full Text]
  48. Wagner S. N., Rebmann V., Willers C. P., Grosse-Wilde H., Goos M. Expression analysis of classic and non-classic HLA molecules before interferon {alpha}-2b treatment of melanoma. Lancet, 356: 220-221, 2000.[Medline]
  49. Fukushima Y., Oshika Y., Nakamura M., Tokunaga T., Hatanaka H., Abe Y., Yamazaki H., Kijima H., Ueyama Y., Tamaoki N. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int. J. Mol. Med., 2: 349-351, 1998.[Medline]
  50. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F. A., Avril M-F., Dausset J., Guillet J. G., Carosella E. D. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA, 95: 4510-4515, 1998.[Abstract/Free Full Text]
  51. Real L. M., Cabrera T., Collado A., Jimenez P., Garcia A., Ruiz-Cabello F., Garrido F. Expression of HLA-G in human tumors is not a frequent event. Int. J. Cancer, 81: 512-518, 1999.[Medline]
  52. Pangault C., Amiot L., Caulet-Maugendre S., Brasseur F., Burtin F., Guilloux V., Drenou B., Fauchet R., Onno M. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens, 53: 335-346, 1999.[Medline]
  53. Frumento G., Franchello S., Palmisano G. L., Nicotra M. R., Giacomini P., Loke Y. W., Geraghty D. E., Maio M., Manzo C., Natali P. G., Ferrara G. B. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by {gamma}IFN treatment. Tissue Antigens, 56: 30-37, 2000.[Medline]
  54. Fuggle S. V., Errasti P., Daar A. S., Fabre J. W., Ting A., Morris P. J. Localization of major histocompatibility complex (HLA-ABC and DR) antigens in 46 kidneys. Transplantation, 35: 385-390, 1983.[Medline]
  55. Natali P. G., Nicotra M. R., Bigotti A., Venturo I., Marcenaro L., Giacomini P., Russo C. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. USA, 86: 6719-6723, 1989.[Abstract/Free Full Text]
  56. Borthwick G. M., Hughes L., Holmes C. H., Davis S. J., Stirrat G. M. Expression of class I and II major histocompatibility complex antigens in Wilms’ tumour and normal developing human kidney. Br. J. Cancer, 58: 753-761, 1988.[Medline]
  57. Moreau P., Adrian-Cabestre F., Menier C., Guiard V., Gourand L., Dausset J., Carosella E. D., Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol., 11: 803-811, 1999.[Abstract/Free Full Text]
  58. Yang Y., Chu W., Geraghty D. E., Hunt J. S. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-{gamma}. J. Immunol., 156: 4224-4231, 1996.[Abstract]
  59. Chu W., Fant M. E., Geraghty D. E., Hunt J. S. Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-{gamma}-activated macrophages but not placental fibroblasts. Hum. Immunol., 59: 435-442, 1998.[Medline]
  60. Mizuno S., Emi N., Kasai M., Ishitani A., Saito H. Aberrant expression of HLA-G antigen in interferon {gamma}-stimulated acute myelogenous leukaemia. Br. J. Haematol., 111: 280-282, 2000.[Medline]
  61. Lefebvre S., Adrian-Cabestre F., Moreau P., Gourand L., Dausset J., Berrih-Aknin S., Carosella E. D., Paul P. Modulation of HLA-G expression in human thymic and amniotic epithelial cells. Hum. Immunol., 61: 1095-1101, 2000.[Medline]
  62. Gobin S. J. P., Peijnenburg A., Keijsers V., van den Elsen P. J. Site {alpha} is crucial for two routes of IFN{gamma}-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity, 6: 601-611, 1997.[Medline]
  63. Lefebvre S., Berrih-Aknin S., Adrian F., Moreau P., Poea S., Gourand L., Dausset J., Carosella E. D., Paul P. A specific ISRE of the distal HLA-G promoter binds IRF-1 and mediates enhancement of this nonclassical histocompatiblity class I gene by IFN-ß. J. Biol. Chem., 276: 6133-6139, 2001.[Abstract/Free Full Text]
  64. Kelley V. E., Fiers W., Strom T. B. Cloned human interferon-{gamma}, but no interferon-ß or -{alpha}, induces expression of HLA-DR determinants by fetal monocytes and myeloid cell lines. J. Immunol., 132: 204-245, 1984.
  65. Riteau B., Rouas-Freiss N., Menier C., Paul P., Dausset J., Carosella E. D. HLA-G2, -G3, and -G4 isoforms expressed as non mature cell-surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J. Immunol., 166: 5018-5026, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. Hastie, J. R. Masters, S. E. Moss, and S. Naaby-Hansen
Interferon-{gamma} Reduces Cell Surface Expression of Annexin 2 and Suppresses the Invasive Capacity of Prostate Cancer Cells
J. Biol. Chem., May 2, 2008; 283(18): 12595 - 12603.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. Feger, E. Tolosa, Y.-H. Huang, A. Waschbisch, T. Biedermann, A. Melms, and H. Wiendl
HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation
Blood, July 15, 2007; 110(2): 568 - 577.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Morandi, I. Levreri, P. Bocca, B. Galleni, L. Raffaghello, S. Ferrone, I. Prigione, and V. Pistoia
Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release
Cancer Res., July 1, 2007; 67(13): 6433 - 6441.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Rouas-Freiss, P. Moreau, S. Ferrone, and E. D. Carosella
HLA-G Proteins in Cancer: Do They Provide Tumor Cells with an Escape Mechanism?
Cancer Res., November 15, 2005; 65(22): 10139 - 10144.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
H. Wiendl, U. Feger, M. Mittelbronn, C. Jack, B. Schreiner, C. Stadelmann, J. Antel, W. Brueck, R. Meyermann, A. Bar-Or, et al.
Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity
Brain, November 1, 2005; 128(11): 2689 - 2704.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Nuckel, V. Rebmann, J. Durig, U. Duhrsen, and H. Grosse-Wilde
HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia
Blood, February 15, 2005; 105(4): 1694 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. LeMaoult, I. Krawice-Radanne, J. Dausset, and E. D. Carosella
HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells
PNAS, May 4, 2004; 101(18): 7064 - 7069.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. I. Torres, M. Le Discorde, P. Lorite, A. Rios, M. A. Gassull, A. Gil, J. Maldonado, J. Dausset, and E. D. Carosella
Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease
Int. Immunol., April 1, 2004; 16(4): 579 - 583.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. J. Morales, J. L. Pace, J. S. Platt, T. A. Phillips, K. Morgan, A. T. Fazleabas, and J. S. Hunt
Placental Cell Expression of HLA-G2 Isoforms Is Limited to the Invasive Trophoblast Phenotype
J. Immunol., December 1, 2003; 171(11): 6215 - 6224.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Singer, V. Rebmann, Y.-C. Chen, H.-T. Liu, S. Z. Ali, J. Reinsberg, M. T. McMaster, K. Pfeiffer, D. W. Chan, E. Wardelmann, et al.
HLA-G Is a Potential Tumor Marker in Malignant Ascites
Clin. Cancer Res., October 1, 2003; 9(12): 4460 - 4464.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Shiroishi, K. Tsumoto, K. Amano, Y. Shirakihara, M. Colonna, V. M. Braud, D. S. J. Allan, A. Makadzange, S. Rowland-Jones, B. Willcox, et al.
Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G